Here are some sample widgets you could interact with from this dashboard:
Tesla and Biogen have similar market caps of roughly $40 billion and both companies have seen their stocks fall by roughly 25% this year. While Biogen stock has declined after it ended phase-3 trials of its Alzheimer’s drug Aducanumab in March, Tesla's has been impacted by slower sales of its premium vehicles and issues with scaling up sales of the mass-market Model 3.However, stock price and corrections aside, the two companies could not be more different. Tesla has much higher revenues, and has posted revenue growth of 65%+ each year over the last 3 years, compared to Biogen which has been growing at single digits. Biogen CEO recently said they need to be more like Tesla. In this analysis, we compare and contrast the key financials and valuation for the two companies and look at which company offers better risk and reward.
Tesla's P/E Based On Exp. 2020 Results Significantly Higher Than Biogen's
Tesla's P/E based on projected 2020 earnings stands at ~60x, versus 7x for Biogen, on account of higher growth projections.
Tesla P/E (2020)
Biogen P/E (2020)
Tesla's Price To Sales Multiple Is Lower Compared To Biogen's
Tesla's P/S, based on projected 2020 revenues, stands at 1.7x versus 3x for Biogen
Tesla P/S (2020)
Biogen P/S (2020)